Heart Failure

Women and African-Americans at Higher Risk of Heart Attack

Women and African-Americans at Higher Risk of Heart Attack

Women and African-Americans at Higher Risk of Heart Attack

 

Women and African-Americans at Higher Risk of Heart Attack

 

NBN Infusions delivers comprehensive services to patients of all ages, from pediatric to geriatric, providing a full range of care for Home Infusion Therapy. NBN Infusions on-site, licensed pharmacy can provide prescription medications, equipment, supplies and skilled nursing care needed for Home Infusion Therapy.

Home Infusion Therapy is a more convenient and cost-effective option than traditional inpatient therapy, with care administered in the comfortable surroundings of one’s own home. Home Infusion Therapy allows for a more active role in one’s own health care. It can also ease stress and anxiety that is sometimes associated with inpatient treatment, resulting in better patient outcomes.

 

Doctors have known for years that atrial fibrillation (AF), or irregular heartbeat, increases the risk for stroke, but now researchers at Wake Forest Baptist Medical Center have shown that it also increases the risk for heart attack. In fact, for women and African Americans, it more than doubles the risk.

 

 The study is published in the Nov. 4 issue of JAMA Internal Medicine.

 

Approximately three million people in the United States have AF and that number is expected to double in the next couple of decades, according to Elsayed Z. Soliman, M.D., director of the Epidemiological Cardiology Research Center (EPICARE) at Wake Forest Baptist and lead author of the study. Patients with AF have three to five times the risk of stroke and double the risk of mortality compared to those without AF.

“AF is a disease of aging and it is common, costly and has lots of complications,” Soliman said. “Our study showed that patients with AF, especially women and African-Americans, are at an increased risk of heart attack compared to those without AF.”

The prospective study included 23,928 participants without coronary heart disease from Reasons for Geographic and Racial Differences in Stroke (REGARDS), a large biracial population-based cohort study. The participants were enrolled between 2003 and 2007 and were followed through December 2009.

In the study, the overall increase in risk of heart attack in those with AF, compared to those without AF, was about 70 percent, even after taking into account other cardiovascular disease risk factors, such as hypertension, high cholesterol, body mass index and history of stroke and vascular disease. That risk was more than double in women and African Americans, but less than 50 percent for men and whites, Soliman said.

These findings add to the growing concerns of the seriousness of AF as a public health burden.

“Traditionally, blood thinners are used to manage AF complications such as stroke, but now there is another dimension to the problem. We need to determine the best strategy to prevent heart attack in AF patients while still dealing with potential stroke risk,” Soliman said. “In our study, individuals taking blood thinners were at lower risk for heart attack from AF, suggesting a potential role for blood thinners in prevention of heart attacks in AF patients.”

 

Originally Posted: Medicalxpress.com 

 

Chronic Heart Failure Trial Using Mesoblast’s Receives FDA Clearance

Chronic Heart Failure Trial Using Mesoblast’s Receives FDA Clearance

Chronic Heart Failure Trial Using Mesoblast’s Receives FDA Clearance

Chronic Heart Failure Trial Using Mesoblast’s, Receives FDA Clearance

 

NBN Infusions delivers comprehensive services to patients of all ages, from pediatric to geriatric, providing a full range of care for Home Infusion Therapy. NBN Infusions on-site, licensed pharmacy can provide prescription medications, equipment, supplies and skilled nursing care needed for Home Infusion Therapy.

Home Infusion Therapy is a more convenient and cost-effective option than traditional inpatient therapy, with care administered in the comfortable surroundings of one’s own home. Home Infusion Therapy allows for a more active role in one’s own health care. It can also ease stress and anxiety that is sometimes associated with inpatient treatment, resulting in better patient outcomes.

 

Mesoblast Limited’s development and commercial partner Teva Pharmaceuticals Industries Ltd has received the United States Food and Drug Administration (FDA clearance to begin phase III trial in patients with chronic congestive heart failure using Mesoblast’s proprietary Mesenchymal Precursor Cells (MPCs). The IND was cleared by the FDA within the minimum 30-day period following submission, and patient recruitment is expected to begin shortly.

 

The multi-centre trial, which will be conducted by Teva, is planned to enrol approximately 1,700 patients and includes two interim analyses of efficacy and/or safety. The clinical protocol was designed after initial consultation with both the FDA and the European Medicines Agency.

 

The phase II trial design is a double-blinded, 1:1 randomized, placebo-controlled study evaluating a single dose of 150 million MPCs delivered via transendocardial injection catheter to the left ventricle of heart failure patients with New York Heart Association (NYHA) class II or III disease and an ejection fraction = 40%. The primary efficacy endpoint of the trial is a time-to-first event analysis of heart failure-related Major Adverse Cardiac Events (HF-MACE), defined as a composite of cardiac related death or resuscitated cardiac death, or non-fatal decompensated heart failure events. These nonfatal decompensated heart failure events require use of intravenous diuretics or aquapheresis during an in-hospital stay or during an outpatient visit. Adjudication of HF-MACE will be performed by an independent, blinded clinical endpoint committee.

 

The MPC dose for the phase III trial was chosen on the basis of results from a 60-patient phase II trial which has shown that heart failure patients treated with the 150 million MPC dose have not experienced any HF-MACE over the three-year follow-up period compared with an HF-MACE incidence of approximately 30 per cent for the control group over the same period.

 

Mesoblast chief executive Silviu Itescu said: “We believe that Mesoblast’s proprietary mesenchymal lineage cells have the potential to offer long-term beneficial outcomes to the millions of patients suffering from heart failure worldwide. Importantly, in 2014 we plan to have products in active phase III clinical trials in all four of our core major therapeutic areas of focus: cardiovascular medicine (congestive heart failure), inflammatory/immune diseases (Crohn’s disease), orthopedics (spinal fusion and intervertebral disc repair) and oncology (acute Graft versus Host Disease, and cord blood expansion in bone marrow transplantation).”

 

Mesoblast Limited is a world leader in the development of biologic products for the broad field of regenerative medicine.

 

Originally Posted: http://www.pharmabiz.com